Please type a plus sign (+) inside this box

FEB 2 7 2002 Under the Paperwork Reduction Act of 1995

PTO/SB/O8A (08-00) Approved for use through 10/31/2002. QMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

Sheet 1 of 2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known						
09/836,746						
April 17, 2001						
Andrew Patron						
1645 59						
Unknown						
41305-253159						

		U.S. Patent 1	Document			
Examiner Initials*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pagaa, Columns, Line: Where Relevant Passages or Relevant Figures Appear
Taw	1	4,591,570		Chang	5/27/1986	
,	2	4,873,313		Crawford, et al.	10/10/1989	
	3	5,512,131		Kumar, et al.	4/30/1996	
	4	5,629,213		Kornguth, et al	5/13/1997	
	5	5,731,152		Maracas, et al.	3/24/1998	
	6	5,733,743		Johnson, et al.	3/31/1998	
	7	5,837,832		Chee, et al.	11/17/1998	
<del></del>	8	5,858,657		Winter, et al.	1/12/1999	
$\neg$	9	5,871,907		Winter, et al.	2/16/1999	
	10	5,969,108		McCafferty, et al	10/19/1999	
- 70	111	5,977,322		Marks, et al.	11/2/1999	

		FOREIGI	N PATENT DOCUMENTS	i		
	T	Foreign Patent Document				ı
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup> Number <sup>4</sup> (if known)	Name of Patenties or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	יז
jeho	12	WO 00/04382	Zyomyx, Inc.	1/27/2000		1
	13	WO 00/04389	Zyomyx, Inc.	1/27/2000		/
·	14	WO 00/04390	Zyomyx, Inc.	1/27/2000		<b>V</b>
	15	WO 00/47996	Illumina, Inc.	8/17/2000		1
	16	WO 00/71992	Illumina, Inc.	11/30/2000		1
	17	WO 00/71995	Illumina, Inc.	11/30/2000		IZ
	18	WO 01/18524	Illumina, Inc.	3/15/2001		T
	19	WO 90/02809	Protein Engineering Corporation	3/22/1990		
	20	WO 98/50773	University of Minnesota	11/12/1998		ľ
	21	WO 98/59362	Ciphergen Biosystems, Inc.	12/30/1998		
	22	WO 98/43086	Kimberly-Clark Worldwide, Inc.	10/1/1998		
$\overline{}$	23	WO 99/40434	Invitrogen	8/12/1999		7 /

Examiner	1	(1/1 , 1)	Date	11/20/23
Signature	7 ] `	Was y	Considered	11/28/02

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not conformation to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

plus sign (+) inside this box

PTO/S8/08A (08-00)

Approved for use inrough 10/31/2002, OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

te for form 1448APTO

JAN 0 3 7003

TRATE TRAD

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known					
Application Number 09/836,746					
Filing Date	April 17, 2001				
First Named Inventor	Andrew Patron	_			
Group Art Unit	1645 35				
Examiner Name	Unknown				
Attorney Docket Number	41305-253159				
Express Mail Certificate	EV 032 108-281	J			

٠.			U.S. PA	TENT DOCUMENTS			
		U.S. Peter	nt Document				
Examiner Initiats*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columna, Lines Where Relevant Passages or Relevant Figures Appear	
	<del></del>	<del></del>					
	<del></del>	<del>                                     </del>	<del></del>		<del> </del>		
	<u> </u>	<del>                                     </del>				CENTY	
						JEON,	
						1 300	
		-		· · · · · · · · · · · · · · · · · · ·		JAN 07 CO	112
						THER IN	) •
<del></del>	+	<del> </del>	<del></del>			-LCH CEMIE	
						JEON,	
		ļ					
				· ·- · · · · · · · · · · · · · · · ·			
		L					

	1	1	oreign Patent Do	cument						
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (If known)		ime of Petentee or ant of Cited Document	Cite	of Publication of Ind Document INDD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	יד
Taw	1	wo	02/39120	A		BIONOVA PHARMACEU- TIALS, INC		5-16-02		
1	2	wo	99/10485	Α		SELECTIVE GENETICS INC.		03-04-99		7
V	3	EP	0 816 511	Α	,	KNOELL HANS FORSCHUNG		01-07-98		~
		<del> </del>			<u> </u>		L			$\pm$

Examiner	(1).	Date	
Signature	7. Wesel	Considered	11/28/10 =
Oigitatare		Considered	7 - 9/0

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents, <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

FEB 2 7 2002

PTO/SB/O8A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number

THE TOTAL PROPERTY.

Substitute for form 1449APTO

Sheet

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995,

(use as many sheets as necessary)

2 of 2

ADEM	nplete if Known	`
Application Number	09/836,746	
Filing Date	April 17, 2001	
First Named Inventor	Andrew Patron	
Group Art Unit	1645 55	
Examiner Name	Unknown	
Attorney Docket Number	41305-253159	
	<u> </u>	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), vokume-issue number(s), publisher, city and/or country where published.	7
+MW	24	Ausubel, F.M. et al., Short Protocols In Molecular Biology, Chapter 9, 2 <sup>rd</sup> Edition, (1992)	7
	25	Barbas, C.F. et al., "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site", Proc. Natl. Acad. Sci., USA, 88:7978-82 (1991)	1
	26	de Bruin, R. et al., "Selection of high-affinity phage antibodies from phage display libraries", Nature Biotechnology, 17:397-399 (April 1999)	
	27	Everall, N.J. et al., "Performance Analysis of an Integrated Process Raman Analyzer Using a Multiplexed Transmission Holographic Grating, CCD Detection, and Confocal Fiber-Optic Sampling", Appl. Spectrosc. 49:610-615 (1995)	
	28	Hamilton, David P. & Antonio Regalado, "In Hot Pursuit of the Proteome", Wall Street Journal (April 5, 2001)	
	29	Hoaglund-Hyzer C.S., et al., "Mobility Labeling for Parallel CID of Ion Mixtures", Anal. Chem., 72:2737-40 (2000)	
	30	Ideue, S., et al., "Conformational change of electrosprayed cytochrome c studied by laser-induced fluorescence", Chemical Physics Letters, 337:79-84, (2001)	
	31	Kubarych, K. "Ultrafast Spectroscopy", at lphys.chem.utoronto.ca/kjk/research.html (2001)	Γ
	32	Luckow, V.A., and Max D. Summers, "Trends in the Development of Baculovirus Expression Vectors", BioTechnology 6:47-55 (1988)	T
	33	Marks, J.D. et al., "Molecular Evolution of Proteins on Filamentous Phage" J. Biol. Chem., 267:16007-16010 (1992)	Ī
	34	Parmley, S.F. and G.P. Smith, et al., "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes", Gene, 73:305-318 (1988)	Ī
	35	Radeke, H.S., et al., "Interactions of (-)-ilimaquinone with methylation enzymes: implications for vesicular-mediated secretion", Chem. Biol., 6, 639-647 (1999)	Ţ
	36	Robertsson, G., "Simple and Efficient Multivariate Calibration of Nonlinear Absorption Spectroscopic Data", Appl. Spectrosc., 55:98-103 (2001).	Γ
	37	Rotman, D., "Nanotech Goes to Work", Technology Review at www.techreview.com/magazine/jan01/rotman.asp (January 2001)	
	38	Sambrook, J. et al, "Current Protocols: Molecular Cloning,"Chapter 16, Cold Spring Harbor Laboratory Press (2000)	I
	39	Sche, P.P. et al., "Display cloning: functional identification of natural product receptors using cDNA-phage display", Chem.& Biol., 6, 707-716 (1999)	
	40	Scott, JK and G.P. Smith, et al, "Searching for peptide ligands with an epitope library", Science 249:386-90 (1990)	
	41	Scultz, G., "Integrated Monolithic Microfabricated Electrospray Device" available at www.cnf.comeli.edu (2001)	L
	42	Soderlind, E. et al., "Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors and in vitro Maturation Systems", Immunol. Rev., 130:109-124 (1992)	
	43	Talbot, D., "Upstream: Computing's New Spin", at www.techreview.com/magazine/jan01/upstream.asp (January 2001)	
	44	"Visualize: DNA Chips", Technology Review at www.techreview.com/magazine/jan01/visualize.asp (January 2001)	
J	45	Winter, G. et al., "Making antibodies By Phage Display Technology", Annu. Rev. Immunol., 12:433-55 (1994)	

Examiner			Date	
	l l	1.1. $200$	D410	(11.0)
Signature	1 `	Wir /	Considered	1/12/12
Orginature		10000	Considered	/ 703

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

'Unique citation designation number. 'Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent end Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents, Washington, DC 20231.

41305-253159

WINLIB01:935064.1